WuXi Biologics (Cayman) (2269.HK) Earnings Analysis

WuXi Biologics (Cayman) (2269.HK) next reports earnings on 2026-08-26, consensus EPS 0.52 HKD. Last quarter (2026-03-24) it missed with EPS 0.679 HKD vs 0.705 HKD est (-3.7%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E 28.46.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 2269.HK next report earnings?

Next earnings date2026-08-26
Consensus EPS estimate0.52 HKD
Revenue estimate13.22B

2269.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-240.679 HKD0.705 HKD-3.7%Miss
2025-08-190.599 HKD0.4902 HKD+22.2%Beat
2025-03-240.2397 HKD0.4688 HKD-48.9%Miss
2024-08-210.3753 HKD0.4396 HKD-14.6%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

2269.HK valuation and analyst view

Trailing P/E28.46
Trailing EPS1.164 HKD
Price / book3.02
Dividend yield0.00%
Market cap160.94B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is WuXi Biologics (Cayman) (2269.HK)'s next earnings date?

WuXi Biologics (Cayman) is next scheduled to report on 2026-08-26, with a consensus EPS estimate of 0.52 HKD and revenue estimate of 13.22B.

Did 2269.HK beat earnings last quarter?

In its 2026-03-24 report, 2269.HK posted EPS of 0.679 HKD versus a 0.705 HKD estimate — a miss of 3.7%.

What is 2269.HK's earnings track record?

Over the last 4 reported quarters with consensus data, 2269.HK beat estimates 1 times (25%).

What is 2269.HK's current P/E ratio and EPS?

2269.HK trades at a trailing P/E of 28.46 on trailing EPS of 1.1637792892667886 HKD.

What do analysts rate 2269.HK?

2269.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.